FDA Approval of CABOMETYX® for Previously Untreated Advanced Renal Cell Carcinoma

Ipsen’s partner Exelixis announces FDA Approval of CABOMETYX®(cabozantinib) Tablets for Previously Untreated Advanced Renal Cell CarcinomaExelixis announced that Cabozantinib was approved by the United States Food and Drug Administration (FDA) for the expanded indication of patients with previously untreated advanced renal cell carcinoma (aRCC) after a priority review process. This is an extension of the previously approved indication, second-line treatment of metastatic renal cancer. The approval is based on data from the CABOSUN study, where cabozantinib demonstrated statistically